Movement Alert|Legend Biotech Falls 5.09% in Regular Trading, Post-Earnings Rating Downgrade Pressure Continues

Market Focus11-21 01:57

On November 21, Legend Biotech fell 5.09% in Regular Trading, trading at $15.28 per share, with turnover of $26.6822 million.

The move was accompanied by continued pressure from a more cautious sell-side stance after the company’s latest quarterly results, with Evercore ISI previously downgrading the stock to In Line and setting a $20 price target, contributing to weaker near-term growth and valuation expectations.

In the latest reported quarter, Legend Biotech posted net income of $51.7 million, reversing from a year-earlier loss, while CARVYKTI net sales rose 36% year over year to about $710 million. However, quarterly revenue of $359.5 million came in slightly below market expectations near $361.5 million, and several firms subsequently lowered target prices, indicating that improving profitability has not fully offset investor caution.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment